Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Lisowska, Katarzyna Marta ^a   Olbryt, Magdalena ^a   Dudaladava, Volha ^b   Pamuła Piłat, Jolanta ^a   Kujawa, Katarzyna ^a   Grzybowska, Ewa ^a   Jarzab, Michał ^a   Student, Sebastian ^c   Rzepecka, Iwona Krystyna ^d   Jarzab, Barbara ^a   Kupryjańczyk, Jolanta ^d  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

^c SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Clasp1; Epithelial ovarian cancer; Gene expression profiling; Genomic medicine; Molecular markers; Oligonucleotide microarrays; Survival time; Tumor histology

Indexed keywords

ARTICLE; BIOTINYLATION; CANCER PROGNOSIS; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE ONTOLOGY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

EID: 84893679459     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00006     Document Type: Article

References (44)

1. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 286(5439):531-7. doi:10.1126/science.286.5439.531
2. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges and opportunities. Sci Transl Med (2013) 5:189sr4. doi:10.1126/scitranslmed.3005785
3. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A (2001) 98:1176-81. doi:10.1073/pnas.98.3.1176
4. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene (2004) 23:8065-77. doi:10.1038/sj.onc.1207959
5. Lee BC, Cha K, Avraham S, Avraham HK. Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol (2004) 4:847-51.
6. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 10:3291-300. doi:10.1158/1078-0432.CCR-03-0409
7. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr., et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol (2004) 165:397-414. doi:10.1016/S0002-9440(10)63306-8
8. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer (2004) 112:14-25. doi:10.1002/ijc.20408
9. Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol (2006) 103:405-16. doi:10.1016/j.ygyno.2006.03.056
10. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol (2005) 96:77-83. doi:10.1016/j.ygyno.2004.08.047
11. Le PC, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, et al. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer (2006) 118:1750-8. doi:10.1002/ijc.21521
12. Pyle-Chenault RA, Stolk JA, Molesh DA, Boyle-Harlan D, McNeill PD, Repasky EA, et al. VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol (2005) 26:245-57. doi:10.1159/000087379
13. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A (2005) 102:7677-82. doi:10.1073/pnas.0502178102
14. Peters DG, Kudla DM, Deloia JA, Chu TJ, Fairfull L, Edwards RP, et al. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev (2005) 14:1717-23. doi:10.1158/1055-9965.EPI-04-0704
15. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res (2004) 10:4427-36. doi:10.1158/1078-0432.CCR-04-0073
16. Davidson B, Zhang Z, Kleinberg L, Li M, Florenes VA, Wang TL, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res (2006) 12:5944-50. doi:10.1158/1078-0432.CCR-06-1059
17. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA (2002) 287:1671-9. doi:10.1001/jama.287.13.1671
18. Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D, et al. Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. Biomed Res Int (2013) 2013:238284. doi:10.1155/2013/238284
19. Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control (2011) 18(1):8-15.
20. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs World Health Organisation Classification of Tumours. Lyon: IARC Press (2003).
21. Barber HR, Sommers SC, Snyder R, Kwon TH. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol (1975) 121:795-807.
22. Rzepecka IK, Szafron L, Stys A, Bujko M, Plisiecka-Halasa J, Madry R, et al. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. Cancer Genet (2012) 205(3):94-100. doi:10.1016/j.cancergen.2011.12.005
23. Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, Madry R, Timorek A, Markowska J, et al. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer (2008) 29(8):27. doi:10.1186/1471-2407-8-27
24. Lisowska KM, Dudaladava V, Jarzab M, Huzarski T, Chmielik E, Stobiecka E, et al. BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. Front Biosci (Elite Ed) (2011) 3:125-36. doi:10.2741/e227
25. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics (2004) 20:93-9. doi:10.1093/bioinformatics/btg382
26. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 190:910-25. doi:10.1016/j.ajog.2004.02.005
27. Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res (2012) 14(4):R110. doi:10.1186/bcr3231
28. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 27(2):151-60. doi:10.1097/PGP.0b013e318161e4f5
29. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 16(5):267-82. doi:10.1097/PAP.0b013e3181b4fffa
30. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol (1999) 72(3):437-42. doi:10.1006/gyno.1998.5275
31. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 34(3):433-43. doi:10.1097/PAS.0b013e3181cf3d79
32. Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is an imported disease: fact or fiction? Curr Obstet Gynecol Rep (2012) 1(1):1-9. doi:10.1007/s13669-011-0004-1
33. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 11:6116-26. doi:10.1158/1078-0432.CCR-04-2509
34. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 62:4722-9.
35. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 14:4376-86. doi:10.1091/mbc.E03-05-0279
36. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer (2004) 90:1814-24. doi:10.1038/sj.bjc.6601791
37. Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res (2005) 11:2123-31. doi:10.1158/1078-0432.CCR-04-2061
38. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 11:6422-30. doi:10.1158/1078-0432.CCR-05-0508
39. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res (2006) 12:690-700. doi:10.1158/1078-0432.CCR-05-1110
40. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry JP, Scolyer RA, Smith AN, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 94:904-13. doi:10.1038/sj.bjc.6603003
41. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, et al. Inconsistency in large pharmacogenomic studies. Nature (2013) 504(7480):389-93. doi:10.1038/nature12831
42. Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol (2011) 158(2):119-23. doi:10.1016/j.ejogrb.2011.04.023
43. Logarinho E, Maffini S, Barisic M, Marques A, Toso A, Meraldi P, et al. CLASPs prevent irreversible multipolarity by ensuring spindle-pole resistance to traction forces during chromosome alignment. Nat Cell Biol (2012) 14(3):295-303. doi:10.1038/ncb2423
44. Patel K, Nogales E, Heald R. Multiple domains of human CLASP contribute to microtubule dynamics and organization in vitro and in Xenopus egg extracts. Cytoskeleton (Hoboken) (2012) 69(3):155-65. doi:10.1002/cm.21005